[Featured Stock] NK Max Rises on Expectations of Proving Alzheimer's Amyloid Beta Hypothesis

[Asia Economy Reporter Hyungsoo Park] NKMAX is showing strong performance. The news that lecanemab, an amyloid beta-targeting Alzheimer’s antibody treatment candidate jointly developed by U.S. Biogen and Japan’s Eisai, has demonstrated cognitive impairment delay effects in Phase 3 clinical trials appears to be influencing the stock price. As results supporting the "amyloid beta hypothesis," which states that amyloid beta protein in the brain is the cause of Alzheimer’s dementia, have emerged, expectations for the Alzheimer’s clinical trials currently underway by NKMAX are also growing.

At 10:52 AM on the 29th, NKMAX was trading at 14,150 KRW, up 6.79% from the previous day.

On the 27th (local time), U.S. Biogen announced that lecanemab, an Alzheimer’s antibody treatment candidate developed with Japan’s Eisai, met the primary endpoint in its Phase 3 clinical trial. In the trial, 27% of patients treated with lecanemab experienced a slowed rate of cognitive decline.

The clinical data can serve as evidence supporting the academic hypothesis that the accumulation of amyloid beta in the brain causes Alzheimer’s. Lecanemab targets amyloid beta protein in the brain.

NKMAX’s SNK works by normalizing microglia cells and ultimately phagocytizing amyloid beta and tau proteins. Currently, NKMAX is conducting a Phase 1 clinical trial for an Alzheimer’s treatment in Mexico.

On the 16th, NKMAX also filed a patent in the U.S. related to neurodegenerative disease treatments using SNK. The patent describes that SNK can cross the blood-brain barrier (BBB), which blocks delivery of therapeutic substances to the brain due to increased expression of 'DNAM-1' and 'CX3CR1' receptors. It also enables regulation of overactivated T cells.

A company representative explained, "NKMAX plans to announce interim results of the Alzheimer’s clinical trial currently underway in Mexico within this year."

This content was produced with the assistance of AI translation services.